BrainsWay is building an investment portfolio alongside its device business: minority stakes in the management companies behind mental health clinic chains, some of whose clinics are BrainsWay customers, plus convertible loans to a home-neuromodulation developer. The balance-sheet line that holds them stood at $28.9 million on September 30, up from $14.7 million at the end of 2025. In the same quarter revenue rose 34 percent to $18.1 million and remaining performance obligations (RPO), which the investor deck calls backlog, grew 31 percent to about $85 million.

Almost all of that increase is new money. BrainsWay bought $14.5 million of these assets in the first nine months of 2026 and the line rose $14.2 million, so the net change in fair value was about minus $230,000, if the line holds only these investments, as it did at year end (Behavioral Wire arithmetic).

Its November investor deck describes the strategy as “A Low-Risk, High-ROI Network That Widens the Moat.” The filings show the portfolio’s size and terms. They do not yet show its returns, or how much of BrainsWay’s reported backlog comes from clinics tied to companies it partly owns.

What BrainsWay owns

The investments are held through Tikva LLC, a Delaware subsidiary formed in 2025 that, in BrainsWay’s words, “makes and holds strategic investments, including in mental health services companies located in the United States and Canada.” Most are management services organizations (MSOs), which provide administrative and other non-clinical services to clinic chains.

InvesteeBusinessStakeAt June 30
NeuroliefHome-use device maker$11M convertible loans, call option to acquire$11.45M
StellaMSO, 20+ clinics, US and Israel~4.7%, preferred$5.63M
AxisMSO, Colorado clinics~37.55%, preferred$2.61M
Tangient (Heading Health)MSO, Texas clinics~10% at purchase; ~14.74% after Aug.$1.71M
HopemarkMSO, Chicago-area clinics~6.4%, preferred$1.52M
BrainStimClinic services, Canada~3.66%, preferred$1.06M
RadialMSO, 27 locations~0.21% at June 30; ~1.92% after July$0.25M
OthersActive Recovery TMS, DGRconvertible loan, other$0.77M

Values are carrying amounts at June 30 from the unaudited half-year statements; Radial’s MSO combined with Mindful Health Solutions’ in August; stakes are as BrainsWay reports them (issued equity or fully diluted). Radial’s $3.0 million in July and Tangient’s $833,000 follow-on in August came after June 30, as did $500,000 in Sound Minds, a behavioral health provider not shown in the table.

The terms explain part of the “low-risk” description. Several clinic stakes are preferred securities that accrue 8 percent a year (Stella, Hopemark and BrainStim), and several let BrainsWay sell the stake back three to four years after purchase: at cost plus 8 percent compounded for Tangient, at the greater of five times EBITDA or cost plus 25 percent compounded for Axis. BrainsWay can appoint a third of the boards of Axis and Tangient. Those are contractual claims on small private companies, and their value depends on those companies being able to pay. The annual report says BrainsWay has “limited historical operating experience and sector-specific expertise in the U.S. healthcare services industry and in the MSO operating model.”

Neurolief is a different bet. It is not a clinic operator, and the deck shows it on a separate home-use neuromodulation slide, not under the “high-ROI network” claim. BrainsWay lent it $5 million in 2025 and $6 million in March 2026, after FDA approved its Proliv Rx device in January for adults with depression who had not improved enough on at least one antidepressant, for use at home or in the clinic. It also holds an option to buy the company: exercisable until 12 months after the March loan, suspended for the next 24 months, then open for a final six months, at a price floored by a minimum enterprise value of $65 million, rising to $90 million. Neurolief was about 46 percent of the portfolio’s June value, and its valuation rests on Monte Carlo models.

Some investees’ clinics are customers

BrainsWay’s half-year statements state the overlap directly. In the first six months of 2026 it recognized $70,000 from one clinic and $140,000 from another (Clinic A and Clinic B), both “serviced by management services organizations in which Tikva holds minority investments,” and says that, “including due to influence considerations,” it will treat these entities as related parties. It says the investment terms are unrelated to the sales contracts. Clinic A owed BrainsWay $135,000 at June 30, more than the $70,000 recognized from it in the half; the note does not say what the balance includes.

That is $210,000, about 0.6 percent of first-half revenue of $32.6 million (Behavioral Wire arithmetic). It is the disclosed amount, not necessarily the total: the statements identify only these two clinics, unnamed, and the third-quarter release gives no related-party figure. BrainsWay’s annual report flags the issue itself: MSOs it invests in “may also provide services to clinics that are, or may in the future become, our customers,” and “These cross-relationships can create actual or perceived conflicts of interest.”

The overlap also appears in announcements. On November 2 BrainsWay announced a “strategic collaboration” with Mindful Health Solutions, whose management company Radial acquired in August. The release also described BrainsWay’s follow-on investment in the MSO serving the Heading Health clinics, but did not mention that BrainsWay holds a stake in Radial, which its filings disclose.

What the deck claims, and what the filings show

The deck pitches clinic economics to investors: about $0.8 million to $1 million of annual revenue and $0.5 million to $0.7 million of annual profit per treatment chair. The slide gives no source and does not say whether the figures are averages, mature clinics or models, or whether they include clinics BrainsWay partly owns. These are BrainsWay’s figures, not established industry economics.

On BrainsWay’s own returns, the record is short: 2025 is audited, the first half of 2026 is not. The portfolio recorded fair-value gains of $162,000 in 2025 and $219,000 in the first half of 2026, $381,000 in all against $24.6 million invested through June. The half-year statements report no exits or distributions. The values are Level 3 estimates, the least observable tier, built on models that include Monte Carlo simulations for Neurolief.

The net hides a wide spread. Stella, bought for $5.0 million in 2025, is carried at $5.63 million. Axis, bought for about $2.3 million in 2025 with $1.0 million more in March 2026, is carried at $2.61 million, which implies a decline of about $770,000 in the half (Behavioral Wire arithmetic from the half-year table). The filings do not say why.

The third quarter may have reversed more. The line was $25.0 million at June 30, BrainsWay bought another $4.3 million of these assets in the quarter, and the line closed at $28.9 million, which implies a fair-value decline of about $450,000 on the same assumption (Behavioral Wire arithmetic). BrainsWay has not published third-quarter fair-value detail.

None of this shows the portfolio is performing poorly. Most positions are less than 18 months old, and some preferred returns and put rights may not be realized for years. It shows that the “high-ROI” description is an expectation, not a reported result.

Why the numbers matter for reading the growth

The capital is now material. BrainsWay spent $14.5 million on these investments in the first nine months of 2026, more than its $13.7 million of operating cash flow and about one and a half times its research spending of $9.6 million (Behavioral Wire arithmetic). The pace is steady, not new: it spent $12.3 million in the same period of 2025. The portfolio now equals just under half of BrainsWay’s $63.4 million in cash, deposits and restricted cash.

BrainsWay discloses the stakes, the terms and the first-half related-party revenue. It does not disclose third-quarter related-party revenue, the share of the $85 million backlog or of new orders that comes from clinics linked to its investees, or what the per-chair figures are based on. Until it does, investors can see that the growth and the investments overlap but cannot measure how much.